Get all your news in one place.
100's of premium titles.
One app.
Start reading
Birmingham Post
Birmingham Post
Business
Jon Robinson

Planned $425m merger under threat after rival's 'unsolicited' takeover bid

A Cheshire drug developer planned $425m merger with a US counterpart is under threat after a rival made an 'unsolicited' takeover bid.

Alderley Park's Redx Pharma and US-based Jounce Therapeutics originally announced the unanimously agreed deal last month.

However, it has now emerged that rival Concentra Biosciences, which is also based in the US, has made a bid to acquire Jounce Therapeutics.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.